Business
AlzeCure Pharma to Present at Redeye Healthcare Day on April 14
STOCKHOLM, SE / ACCESS Newswire / April 7, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...
About this update from Alzecure Pharma Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / April 7, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that it will participate at Redeye Healthcare Day on April 14, where CEO Martin Jönsson will give a company presentation and answer questions about the latest developments and AlzeCure's plans for the future.","length":464,"tagName":"p"},{"type":"text","content":"The participation will be broadcast live and can be followed on: https://www.redeye.se/events/1145882/redeye-healthcare-day-2026","length":128,"tagName":"p"},{"type":"text","content":"The presentation will also be available afterwards on AlzeCure's company page on Redeye's website www.redeye.se/company/alzecure-pharma and on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/.","length":237,"tagName":"p"},{"type":"text","content":"Presentation time: April 14, 15:30 CESTVenue: Redeye, Mäster Samuelsgatan 42, Stockholm","length":88,"tagName":"p"},{"type":"text","content":"For more information, please contact","length":36,"tagName":"p"},{"type":"text","content":"Martin Jönsson, CEOTel: +46 707 86 94 [email protected]","length":75,"tagName":"p"},{"type":"text","content":"About AlzeCure Pharma AB (publ)","length":31,"tagName":"p"},{"type":"text","content":"AlzeCure® is a Swedish clinical stage biotech company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.","length":493,"tagName":"p"},{"type":"text","content":"NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. NeuroRestore has received an EU grant from the European Innovation Council and is being prepared for ph...